Function, work productivity, and quality of life measures in a phase 3, randomized, placebo-controlled, double-blind, multicenter, 12-week study of the safety and efficacy of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea
Introduction: Excessive sleepiness in patients with obstructive sleep apnea (OSA) is associated with reductions in health-related quality-of-life (HRQoL), impaired functioning at work, and negative impact on daily activities. The efficacy of solriamfetol (JZP-110), a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, was evaluated in a phase 3 study in patients with excessive sleepiness due to OSA.
Source: Sleep Medicine - Category: Sleep Medicine Authors: C. Drake, R. Bogan, H. Benes, T. Stern, K.F. Villa, D. Chen, L. Carter, H. Wang, J. Black, T. Weaver Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
More News: Narcolepsy | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine | Study